perhexiline has been researched along with Cardiac Failure in 21 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization." | 9.20 | Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. ( Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z, 2015) |
| " In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome." | 9.19 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. ( Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S, 2014) |
| "The re-purposing of the anti-anginal drug perhexiline (PHX) has resulted in symptomatic improvements in heart failure (HF) patients." | 8.93 | Pleiotropic mechanisms of action of perhexiline in heart failure. ( Bannister, ML; George, CH; Mitchell, AN; Preece, R; Yousef, Z, 2016) |
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 6.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization." | 5.20 | Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. ( Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z, 2015) |
| " In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome." | 5.19 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. ( Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S, 2014) |
| "The re-purposing of the anti-anginal drug perhexiline (PHX) has resulted in symptomatic improvements in heart failure (HF) patients." | 4.93 | Pleiotropic mechanisms of action of perhexiline in heart failure. ( Bannister, ML; George, CH; Mitchell, AN; Preece, R; Yousef, Z, 2016) |
| "Heart failure is a major cause of morbidity and mortality in society." | 2.76 | Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. ( Abozguia, K; Beadle, RM; Frenneaux, MP; Leon, FL; Patel, K; Wagenmakers, A; Williams, LK; Yousef, Z, 2011) |
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 2.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "Several therapies commonly used for the treatment of acute heart failure syndromes (AHFS) present some well-known limitations and have been associated with an early increase in the risk of death." | 2.44 | Overview of emerging pharmacologic agents for acute heart failure syndromes. ( Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ceccarelli, SM | 1 |
| Chomienne, O | 1 |
| Gubler, M | 1 |
| Arduini, A | 1 |
| Singh, S | 1 |
| Beadle, R | 1 |
| Cameron, D | 1 |
| Rudd, A | 1 |
| Bruce, M | 1 |
| Jagpal, B | 1 |
| Schwarz, K | 1 |
| Brindley, G | 1 |
| Mckiddie, F | 1 |
| Nightingale, P | 1 |
| Lang, C | 1 |
| Dawson, D | 1 |
| Frenneaux, M | 2 |
| Cappola, TP | 1 |
| Beadle, RM | 3 |
| Williams, LK | 2 |
| Kuehl, M | 1 |
| Bowater, S | 1 |
| Abozguia, K | 2 |
| Leyva, F | 1 |
| Yousef, Z | 3 |
| Wagenmakers, AJ | 1 |
| Thies, F | 1 |
| Horowitz, J | 2 |
| Frenneaux, MP | 6 |
| Davogustto, G | 1 |
| Taegtmeyer, H | 1 |
| Loudon, BL | 1 |
| Noordali, H | 1 |
| Gollop, ND | 1 |
| Madhani, M | 1 |
| George, CH | 1 |
| Mitchell, AN | 1 |
| Preece, R | 1 |
| Bannister, ML | 1 |
| Heggermont, WA | 1 |
| Papageorgiou, AP | 1 |
| Heymans, S | 1 |
| van Bilsen, M | 1 |
| Fragasso, G | 1 |
| Salerno, A | 1 |
| Spoladore, R | 1 |
| Bassanelli, G | 1 |
| Arioli, F | 1 |
| Margonato, A | 1 |
| Di Napoli, P | 1 |
| Palaniswamy, C | 1 |
| Mellana, WM | 1 |
| Selvaraj, DR | 1 |
| Mohan, D | 1 |
| Horowitz, JD | 2 |
| Chirkov, YY | 1 |
| Kennedy, JA | 1 |
| Sverdlov, AL | 1 |
| Patel, K | 1 |
| Leon, FL | 1 |
| Wagenmakers, A | 1 |
| Lee, L | 1 |
| Campbell, R | 1 |
| Scheuermann-Freestone, M | 1 |
| Taylor, R | 1 |
| Gunaruwan, P | 1 |
| Williams, L | 2 |
| Ashrafian, H | 3 |
| Fraser, AG | 1 |
| Clarke, K | 1 |
| deGoma, EM | 1 |
| Vagelos, RH | 1 |
| Fowler, MB | 1 |
| Ashley, EA | 1 |
| De Luca, L | 1 |
| Mebazaa, A | 1 |
| Filippatos, G | 1 |
| Parissis, JT | 1 |
| Böhm, M | 1 |
| Voors, AA | 1 |
| Nieminen, M | 1 |
| Zannad, F | 1 |
| Rhodes, A | 1 |
| El-Banayosy, A | 1 |
| Dickstein, K | 1 |
| Gheorghiade, M | 1 |
| Opie, LH | 1 |
| Silver, PJ | 1 |
| Monteforte, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF)[NCT00839228] | Phase 2 | 70 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| Metabolic Manipulation in Chronic Heart Failure[NCT00841139] | Phase 2 | 50 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery[NCT00845364] | Phase 2/Phase 3 | 290 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy[NCT00989508] | Phase 2/Phase 3 | 220 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for perhexiline and Cardiac Failure
| Article | Year |
|---|---|
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm.
Topics: Cardiovascular Agents; Heart Failure; Humans; Nitrites; Perhexiline | 2016 |
Pleiotropic mechanisms of action of perhexiline in heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Design; Heart Failure; Humans | 2016 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Di | 2016 |
Metabolic therapy of heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Fatty Acids, Nonesterified; Heart | 2008 |
Metabolic modulation: a new therapeutic target in treatment of heart failure.
Topics: Acetanilides; Carnitine O-Palmitoyltransferase; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glu | 2011 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricula | 2010 |
Emerging therapies for the management of decompensated heart failure: from bench to bedside.
Topics: Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Cardiac Myosins; Cardiotonic A | 2006 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans | 2008 |
4 trials available for perhexiline and Cardiac Failure
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
Topics: Cardiovascular Agents; Clinical Protocols; Double-Blind Method; Heart Failure; Humans; Outcome Asses | 2014 |
Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiovascular Agents; Double-Blind Method; Echocardiography; Energy Metabo | 2015 |
Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.
Topics: Adenosine Triphosphate; Cardiac Catheterization; Cardiomyopathy, Dilated; Cardiovascular Agents; Dou | 2011 |
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Echocardiography, Stress; Fatty Acids; Female; Glucose | 2005 |
8 other studies available for perhexiline and Cardiac Failure
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; E | 2011 |
Perhexiline: lessons for heart failure therapeutics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
Reply: Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
The metabolic treatment of coronary artery disease and heart failure.
Topics: Carnitine O-Palmitoyltransferase; Coronary Artery Disease; Epoxy Compounds; Heart Failure; Humans; P | 2009 |
The pathophysiology of heart failure: a tale of two old paradigms revisited.
Topics: Cardiovascular Agents; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Heart Failu | 2008 |
Drugs and the heart. III. Calcium antagonists.
Topics: Angina Pectoris; Aniline Compounds; Arrhythmias, Cardiac; Calcium; Cardiomegaly; Diuretics; Heart Di | 1980 |
Differential effects of pharmacological modulators of cardiac myofibrillar ATPase activity in normal and myopathic (BIO 14.6) hamsters.
Topics: Adenosine Triphosphatases; Animals; Anti-Arrhythmia Agents; Bepridil; Calcium; Calcium Channel Block | 1988 |